FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 第 2 頁 共 12 頁 v 1.3.0 FF305 | 7). | 購回股份(或其他證券)但沒有註銷 | 282,748 | 0.01 % | RMB | 70.77 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年7月4日，本公司實施2025年第一次回購，并回購282,748股A | | | | | | | 股股份。 | | | | | | | 變動日期 2025年7月4日 | | | | | | 8). | 購回股份(或其他證券)但沒有註銷 | 287,026 | | | | | | | | 0.01 % | RMB | 69.71 | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 通函，及於2 ...

Market Overview - The Shanghai Composite Index rose by 0.48% to close at 3683.46 points, with a daily high of 3688.63 points [1] - The Shenzhen Component Index increased by 1.76% to close at 11551.36 points, reaching a peak of 11558.59 points [1] - The ChiNext Index saw a significant rise of 3.62%, closing at 2496.5 points, with a maximum of 2497.86 points [1] Margin Trading and Securities Lending - The total margin trading and securities lending balance in the Shanghai and Shenzhen markets reached 20396.33 billion yuan, with a financing balance of 20254.43 billion yuan and a securities lending balance of 141.9 billion yuan [2] - This represents an increase of 116.84 billion yuan compared to the previous trading day [2] - The Shanghai market's margin trading balance was 10388.87 billion yuan, up by 34.31 billion yuan, while the Shenzhen market's balance was 10007.46 billion yuan, increasing by 82.53 billion yuan [2] Fund Issuance - Five new funds were launched yesterday, including: Changcheng SSE Sci-Tech Innovation Board Comprehensive Index C, Bank of China CSI Hong Kong Stock Connect Internet Index Initiation A, Bank of China CSI Hong Kong Stock Connect Internet Index Initiation C, Changcheng SSE Sci-Tech Innovation Board Comprehensive Index A, and General Aviation ETF [4] Top Margin Buying Stocks - The top three stocks by margin buying amount were: - Dongfang Fortune with 40.29 billion yuan - Xinyi Sheng with 22.54 billion yuan - Zhongji Xuchuang with 19.07 billion yuan [3] Top Net Buying on Dragon and Tiger List - The top ten net buying amounts on the Dragon and Tiger list were led by: - China Great Wall with 37309.97 million yuan - Guangku Technology with 25989.54 million yuan - Robot Technology with 20787.66 million yuan [6]

高盛主要观点如下： 资金流向上 —— 高盛的交易平台买入呈现 1.2 倍净卖出状态。消费和科技板块是平台最活跃的主题(双 向交易并存，但消费股更适合卖出而科技股更宜买入)。消费板块呈现双向流动，餐饮类股遭遇部分抛 售，而普拉达等零售股则买卖交投活跃。科技板块中，持续在硬科技领域获得买单，但对腾讯音乐等冲 高个股转为卖出。网易也获得较大力度买入。医疗保健 / 制药板块更受青睐 —— 翰森制药虽呈双向交 易但买方更占优势。 香港股市创下自五月初以来的最佳单日表现。 从行业板块来看，医疗保健、科技和消费板块领涨 —— 在中国政府宣布对符合条件的个人消费贷款实 施贴息计划后，国内零售商与消费医疗企业的股价应声上扬。医疗板块中，信达生物(+9%)、药明康德 (+6.2%)、翰森制药(+5.4%)涨幅居前。科技板块以腾讯音乐(+15.6%)表现最为亮眼，其财报大幅超出预 期，多家投行同步上调目标价。其他涨幅显著的个股包括阿里巴巴(+6.1%)、哔哩哔哩(+7.4%)，华虹半 导体(+5.9%)等芯片股亦表现强势。能源与电信板块表现滞后，虽维持涨势但明显跑输大盘，部分资金 正轮动至成长股。 智通财经APP获悉，高盛发布研报 ...

Summary of Wuxi Apptec Conference Call Company Overview - **Company**: Wuxi Apptec - **Sector**: Healthcare Technology & Distribution - **Description**: Wuxi Apptec is a leading platform providing services across the pharmaceutical development cycle for small molecule drugs, including drug discovery, manufacturing, testing services for medical devices, and R&D for precision medicine. The company operates 29 sites globally, including in China, the US, and the EU [10][11]. Key Financial Performance - **1H25 Revenue**: Total revenue reached RMB 20.8 billion, representing a 20.6% YoY increase, with continuing operations growing by 24.2% YoY [2][3]. - **Backlog Growth**: The total backlog increased by 37.2% YoY to RMB 56.69 billion, indicating strong future revenue potential [2][22]. - **Net Profit**: Attributable net profit was RMB 8.3 billion, exceeding the consensus estimate of RMB 7.0 billion [2]. - **Adjusted Non-IFRS Net Profit**: This figure was RMB 6.3 billion, reflecting a 44.4% YoY growth, surpassing the full-year expectation of 13.8% [2][3]. - **Revenue by Region**: US revenue grew by 38.4% YoY, while Europe and China saw increases of 9.2% and a decline of 5.2%, respectively [2][20]. Operational Efficiency - **Gross Profit Margin (GPM)**: Improved to 43.8% in 1H25, up by 4.9 percentage points YoY [3]. - **Operating Efficiency**: The ratio of selling/admin/R&D expenses to total revenue improved, with selling expenses at 1.8%, admin at 5.7%, and R&D at 2.5% [3]. - **Full-Year Guidance**: The company raised its guidance for continuing operations and total revenue growth from 10-15% to 13-17% YoY, projecting total revenue of RMB 42.5-43.5 billion for FY25 [3]. Investment Rationale - **Buy Rating**: The company maintains a Buy rating due to robust backlog growth, strong US revenue performance, and its position as a leader in the CXO sector amidst geopolitical tensions [1][11]. - **Market Position**: Wuxi Apptec is viewed as a proxy for the China innovative drug sector, benefiting from a re-rating of market multiples [11]. - **Funding Environment**: There are positive signals in the overseas biotech funding market, which is expected to support Wuxi Apptec's growth [11]. Financial Estimates and Valuation - **Price Objective**: The price objective has been raised to HK$ 115.70 from HK$ 86.20, reflecting a 19.7x adjusted PE for 2026E [1][29]. - **Earnings Per Share (EPS)**: Adjusted EPS estimates for 2025E, 2026E, and 2027E are RMB 4.63, RMB 5.46, and RMB 6.45, respectively, with YoY changes of 20.8%, 18.1%, and 18.1% [4][15]. - **Free Cash Flow**: Expected to grow significantly, with projections of RMB 3.18, RMB 3.93, and RMB 5.49 per share for 2025E, 2026E, and 2027E [4]. Risks and Considerations - **Downside Risks**: Include strained Sino-U.S. relations, potential slowdowns in pharma/biotech investments, margin pressures from competition, and possible cuts to Medicare and Medicaid [30]. - **Upside Risks**: Faster growth in CRO/CDMO projects and higher-than-expected customer acquisition could enhance revenue [30]. Conclusion Wuxi Apptec demonstrates strong financial performance and operational efficiency, with a positive outlook supported by robust backlog growth and a favorable market position. The raised price objective and earnings estimates reflect confidence in the company's long-term growth potential.

Summary of Key Points Core Viewpoint - As of August 13, the total market financing balance reached 2.03 trillion yuan, marking an increase of 11.696 billion yuan from the previous trading day, with a continuous rise over three consecutive trading days [1]. Financing Balance and Individual Stocks - The financing balance for the Shanghai Stock Exchange was 1.029 trillion yuan, up by 3.493 billion yuan, while the Shenzhen Stock Exchange's balance was 996.38 billion yuan, increasing by 8.169 billion yuan. The Beijing Stock Exchange saw a financing balance of 66.17 million yuan, up by 3.368 million yuan [1]. - On August 13, a total of 2,028 stocks experienced net financing inflows, with 624 stocks having net inflows exceeding 10 million yuan. Notably, 43 stocks had net inflows over 100 million yuan [1]. - The top three stocks by net financing inflow were Dongfang Caifu with 783 million yuan, followed by WuXi AppTec with 671 million yuan, and New Yisheng with 517 million yuan [1]. Industry and Sector Analysis - Among the stocks with net inflows exceeding 100 million yuan, the electronics, communications, and machinery equipment sectors were the most prominent, with 8, 6, and 5 stocks respectively [1]. - In terms of board distribution, 28 stocks with significant net inflows were from the main board, 12 from the ChiNext board, and 3 from the Sci-Tech Innovation board [1]. Financing Balance as a Percentage of Market Capitalization - The average financing balance as a percentage of the circulating market value for stocks with significant net inflows was 3.97%. The stock with the highest financing balance relative to its market value was Longyang Electronics, with a financing balance of 480 million yuan, accounting for 10.65% of its market value [2]. - Other notable stocks with high financing balance percentages included Jianghuai Automobile at 9.79%, Dongfang Caifu at 7.33%, and Dazhu Laser at 7.04% [2]. Detailed Stock Performance - A detailed ranking of net financing inflows on August 13 included: - Dongfang Caifu: 2.46% increase, net inflow of 783 million yuan, financing balance of 2.411 billion yuan, 7.33% of market value [2]. - WuXi AppTec: 7.23% increase, net inflow of 671 million yuan, financing balance of 546 million yuan, 2.24% of market value [2]. - New Yisheng: 15.45% increase, net inflow of 517 million yuan, financing balance of 768 million yuan, 3.67% of market value [2]. - Other stocks with significant net inflows included Guizhou Moutai, Guotai Junan, and Feilihua, among others [1][2].

Wind统计显示，8月13日，申万31个一级行业中有26个行业获融资净买入，其中，非银金融行业获融资 净买入额居首，当日净买入23.13亿元；获融资净买入居前的行业还有通信、医药生物、机械设备、计 算机、电子、银行等，净买入金额分别为19.03亿元、17.06亿元、14.83亿元、14.71亿元、13.19亿元、 13.12亿元。 个股方面，8月13日有2028只个股获融资净买入，净买入金额在5000万元以上的有112股。其中，17股获 融资净买入额超2亿元。东方财富获融资净买入额居首，净买入7.83亿元；融资净买入金额居前的还有 药明康德、新易盛、贵州茅台、国泰海通、菲利华、工业富联、中信证券、东山精密等，净买入额分别 为6.71亿元、5.17亿元、4.56亿元、4.5亿元、4.45亿元、3.68亿元、3.53亿元、3.07亿元。 ...

Core Viewpoint - The article highlights the increasing trend of interim dividend announcements among A-share listed companies, with a total proposed payout of 829.02 billion yuan as of August 13, 2025, reflecting a strong commitment to shareholder returns and stable financial management [1] Group 1: Interim Dividend Trends - As of August 13, 2025, 65 A-share listed companies have disclosed their interim dividend plans, with a total proposed payout of 829.02 billion yuan [1] - Several companies are initiating interim dividends for the first time, with industry leaders leading the way in distributing substantial dividends [1][2] - The trend of increasing cash dividends aligns with regulatory encouragement and investor expectations, indicating a positive market reception [1] Group 2: Company-Specific Dividend Plans - Hikvision plans to distribute a cash dividend of 4 yuan per 10 shares, totaling approximately 3.6 billion yuan, supported by a revenue of 418.18 billion yuan and a net profit of 56.57 billion yuan for the first half of the year [2] - Changshu Bank has achieved double-digit growth in revenue and net profit for 16 consecutive quarters, proposing a cash dividend of 0.15 yuan per share, totaling 4.97 billion yuan, which is 25.27% of its net profit [3] - Weisheng Information plans to distribute a cash dividend of 2.5 yuan per 10 shares, totaling 1.22 billion yuan, with a net profit of 3.05 billion yuan, reflecting a 40% payout ratio [3] Group 3: Industry Leaders and Their Performance - China Mobile reported a revenue of 543.8 billion yuan and a net profit of 84.2 billion yuan, proposing an interim dividend of 2.75 HKD per share, totaling approximately 54.2 billion yuan [4] - China Unicom achieved a revenue exceeding 200 billion yuan and a profit of 17.7 billion yuan, proposing a dividend of 0.1112 yuan per share, totaling around 3.48 billion yuan [5] - CATL, benefiting from dual business segments, reported a revenue of 178.9 billion yuan and a net profit of 30.5 billion yuan, proposing a cash dividend of 10.07 yuan per 10 shares, totaling 4.57 billion yuan [5] - WuXi AppTec achieved a revenue of 207.99 billion yuan and a net profit of 85.61 billion yuan, proposing a cash dividend of 3.5 yuan per 10 shares, totaling 1.003 billion yuan [5]

Market Performance - Hong Kong stock market recorded its best single-day performance since early May, driven by interest subsidy policies, improving geopolitical conditions, and rising risk appetite ahead of tech giants' earnings season [1][2] - The Hang Seng Index saw a significant increase despite net outflows of $1 billion from southbound funds, indicating growing local market risk sentiment [1] Sector Performance - Healthcare, technology, and consumer sectors led the gains, with notable stock price increases following the Chinese government's announcement of interest subsidies for eligible personal consumption loans [2] - Key performers included Innovent Biologics (+9%), WuXi AppTec (+6.2%), and Hansoh Pharmaceutical (+5.4%) in the healthcare sector, while Tencent Music (+15.6%) and Alibaba (+6.1%) excelled in technology [2] Tencent Financial Results - Tencent reported a 15% year-on-year revenue growth in Q2, exceeding expectations, with operating profit up 18% [3] - Game revenue increased by 22%, and advertising revenue rose by 20%, both surpassing forecasts [3] - Gross margin improved to 57%, reflecting strong performance in high-margin business areas despite previous concerns over AI-related capital expenditures [3] Goldman Sachs Ratings - Goldman Sachs initiated a "Buy" rating for Damai Entertainment, setting a 12-month target price of HK$1.38, citing its leading position in live event ticketing and IP licensing in China [4] - The company is expected to benefit from the growing demand for live entertainment, with projections indicating a sixfold growth in the sector over the next five years [4] Baidu's Business Outlook - Baidu is undergoing a significant transformation in its search business, with expectations of declining advertising revenue due to shifts in user behavior towards AI and social media [8][11] - The cloud business is anticipated to grow by 25% year-on-year in 2025, driven by strong demand for AI training and subscription models [8][11] Tencent Music Highlights - Tencent Music's Q2 revenue reached 4.4 billion RMB, a year-on-year increase of 18%, driven by strong online music service performance [12][13] - The number of SVIP users surpassed 15 million, contributing to an increase in average revenue per user (ARPU) [12][13] - Non-GAAP operating profit margin expanded to 33.5%, supported by effective cost control [12][13] Yonghui Superstores and Baoshan International - Yonghui Superstores reported a 13% year-on-year increase in net profit for Q2, driven by non-operating income and lower tax expenses [18] - Baoshan International's Q2 revenue declined by 12%, with same-store sales showing a significant drop, although gross margin exceeded expectations [19][20]

Stock Market Activity - The total trading amount for Shanghai Stock Connect today was 137.85 billion, while Shenzhen Stock Connect totaled 139.34 billion [1] - The top traded stocks in Shanghai included Kweichow Moutai with 3.15 billion, WuXi AppTec with 2.39 billion, and Cambricon Technologies with 2.22 billion [2] - In Shenzhen, the leading stocks were CATL with 3.96 billion, Zhongji Xuchuang with 2.45 billion, and NewEase with 2.31 billion [3] Sector Performance - The sectors with the highest gains included non-ferrous metals, PEEK materials, CPO, and photolithography machines, while coal, banking, ports, and logistics sectors saw declines [4] - The non-bank financial sector had a net inflow of 4.39 billion, followed by securities with 4.30 billion and communications with 1.93 billion [5] - The food and beverage sector experienced the largest net outflow of 2.33 billion, followed by semiconductors with 2.28 billion and banking with 1.96 billion [6] ETF Trading - The top ETFs by trading amount included Hong Kong Securities ETF with 24.64 billion, Hong Kong Innovative Drug ETF with 9.89 billion, and Hang Seng Technology ETF with 5.38 billion [7] - The ETFs with the highest growth in trading amount compared to the previous trading day included Broker ETF with 0.35 billion (up 224.38%) and Communication ETF with 1.04 billion (up 144.84%) [8] Futures Market - The four major futures contracts saw significant increases in both long and short positions, with the IH contract showing balanced increases, while the IF contract had slightly more short positions [9] Institutional Activity - Institutional buying was notable in stocks like Huadian Power with a 10% increase and 225 million bought, while stocks like Huadian Technology saw significant selling [10] - The overall activity of institutions decreased, with notable buying in PCB concept stocks and significant selling in PEEK material stocks [11] Retail Investor Activity - Retail investors showed moderate activity, with significant buying in China Great Wall and selling in Hengbao [12][13] - Quantitative funds also showed increased activity, with notable buying in Huasheng Technology and selling in Sainuo Medical [14]

文/新苏商记者张静文 具体来看，连云港恒瑞医药以4156亿元的总市值排在江苏A股上市公司市值第一位。今年以来，恒瑞医 药发展稳健，7月底，公司与英国制药巨头GSK达成约120亿美元合作协议，首付款5亿美元，刷新中国 药出海纪录。 前不久，美国《制药经理人》杂志发布了2025年全球制药企业50强榜单，恒瑞医药位列第46名，排名上 升2位。 同属医药生物行业的无锡药明康德以2894亿元的总市值紧随其后。2025上半年财报显示，上半年药明康 德实现营收207.99亿元，同比增长20.64%，实现归母净利润85.61亿元，同比增长101.92%。财报公布次 日，药明康德股价大涨7.72%。 东山精密在7月17日市值首次突破千亿大关，当天股票涨停。截至今日收盘，公司最新市值约为1090亿 元。从2024年年初至今，东山精密股价从17.71元/股涨至59.5元/股，涨幅高达236%。 8月13日，市场全天震荡走高，沪指突破去年10月8日高点，创近4年新高。沪深两市全天成交额2.15万 亿元，较上个交易日放量2694亿元，时隔114个交易日重回2万亿元上方，全市场超2700只个股上涨。 得益于行业好转和出海业务增长迅猛，徐 ...